Ergoteles’s Rani Therapeutics RANI Stock Holding History

Ergoteles’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,901	Closed	-$106K	–	1677
2022 Q4	$106K	Buy	+17,901	New	+$131K	﹤0.01%	1215

Other funds holding RANI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

ASGS

Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

Ergoteles's RANI Position: Q1 2023 in Review

Ergoteles sold out of Rani Therapeutics (RANI) in Q1 2023, closing a stake of 17,901 shares — an estimated $106K sold.

Ergoteles first reported a position in RANI in Q4 2022 and held it in 1 quarter. The position peaked at $106K in Q4 2022. 36 funds tracked by Wall St. Rank hold RANI as of Q1 2023.

Ergoteles reported no remaining Rani Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 17,901 Rani Therapeutics shares in Q1 2023, an estimated $106K.
Ergoteles first reported a position in Rani Therapeutics in Q4 2022 and held it in 1 quarter.
Ergoteles's Rani Therapeutics position peaked at $106K in Q4 2022.
36 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.